Cytec Industries Inc. (NYSE:CYT) revenue growth trails the industry average of 14.1%. Since the same quarter one year prior, revenues slightly increased by 2.0%. Growth in the company’s revenue appears to have helped boost the earnings per share. Cytec Industries Inc. (NYSE:CYT) shares after opening at $97.57 moved to $98.37 on last trade day and at the end of the day closed at $98.18. Company price to sales ratio in past twelve months was calculated as 1.81 and price to cash ratio as 23.14. Cytec Industries Inc. (NYSE:CYT) showed a positive weekly performance of 3.34%.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) Net loss for 2013 was $130.7 million, or basic and diluted net loss per share available to common stockholders of $1.32, compared with net loss for 2012 of $91.8 million, or basic and diluted net loss per share available to common stockholders of $1.28. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) shares advanced 5.31% in last trading session and ended the day on $4.76. MACK return on equity ratio is recorded as 349.10% and its return on assets is -80.40%. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) yearly performance is -16.93%.
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on 9 April announced the availability of HETLIOZ™. HETLIOZ™ is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares moved up 8.25% in last trading session and was closed at $14.70, while trading in range of $13.53 – $14.77. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date (YTD) performance is 18.45%.
Aastrom Biosciences Inc. (NASDAQ:ASTM) revealed that it has entered into a definitive agreement to buy Sanofi’s Cell Therapy and Regenerative Medicine (CTRM) business. The company agreed on the takeover in consideration of total $6.5 million, where $4 million is payable in cash at the close of the transaction and the remaining $2.5 million to be paid in a mode of a promissory note. Aastrom Biosciences Inc. (NASDAQ:ASTM) weekly performance is 20.66%. On last trading day company shares ended up $4.38. Aastrom Biosciences Inc. (NASDAQ:ASTM) distance from 50-day simple moving average (SMA50) is 14.51%. Analysts mean target price for the company is $4.25.